pfizer Archives - Amazing Health Advances

Kansas Sues Pfizer for Misleading the Public About the Risks of its mRNA COVID-19 Vaccines

The AHA! Team — Wed, 02 Oct 2024 08:06:39 +0000

Cassie B. via Natural News – The state of Kansas has filed a consumer protection lawsuit against the pharmaceutical company Pfizer, accusing it of misleading the public when it comes to both the safety and efficacy of its highly controversial mRNA COVID-19 vaccines. According to the suit, Pfizer knew that its vaccine came with significant adverse effects and manipulated its safety trials in order to deceive the public, violating Kansas’s consumer protection laws as well as previous consent judgments. The suit cites a slew of supporting evidence, including scientific and government research, press releases, interviews, and news reports demonstrating Pfizer’s misdeeds. According to the suit, Pfizer knew that its vaccine came with significant adverse effects and manipulated its safety trials For example, they cited a paper from the New England Journal of Medicine and an FDA memo to support the allegation that Pfizer purposely destroyed the control group of a COVID vaccine trial by providing participants with access to the jab. This made it impossible to fairly evaluate the safety of the vaccine by comparing a vaccinated group to one that was not vaccinated, the lawsuit alleges. In addition, they cited two articles from the British Medical Journal indicating that Pfizer delayed the release of vaccine trial data intentionally and only tested healthy patients in its vaccine trials in a marked departure from what is considered protocol. They cited two articles from the British Medical Journal indicating that Pfizer delayed the release of vaccine trial data intentionally To support their allegation that the company purposefully misrepresented the vaccine’s safety, they included press releases from Pfizer and interviews with CEO Albert Bourla in which the vaccine is presented as safe and effective. The lawsuit also refers to a Freedom of Information Act (FOIA) request filed by the watchdog group Public Health and Medical Professionals for Transparency in America with the FDA, through which they obtained information about the vaccine. From this FOIA suit, the group acquired an internal Pfizer database listing adverse events that was never shared with the public and contained far more incidents than those listed in the public-facing Vaccine Adverse Event Reporting System. In total, the internal database showed nearly 160,000 adverse events, along with more than 1,200 fatalities among the millions of people who received the vaccine as of February 2021. Heart problems and pregnancy complications weren’t disclosed to public The lawsuit also focused on specific health issues that have been coming to light since the vaccine rollout, such as heart problems. Not long after the vaccine started being administered to young people, it became apparent that it was having an adverse effect on their hearts, particularly young men. Myocarditis, which occurs when the middle layer of the heart’s wall becomes inflamed, can weaken the organ and has the potential to cause heart failure. The lawsuit alleges: “Pfizer said its COVID-19 vaccine was safe even though it knew its COVID-19 vaccine was connected to serious adverse events, including myocarditis and pericarditis, failed pregnancies, and deaths. Pfizer concealed this critical safety information from the public.” Another point of concern cited by the lawsuit is the dangers of the vaccine in pregnant women. It maintains that the company knew from a study that rat fetuses had trouble getting pregnant and implanting embryos and that their fetuses suffered malformations yet insisted to the public that the jab did not present any risk to pregnant women. The rat study was another revelation from the FOIA lawsuit, but the Kansas lawsuit also notes that Pfizer’s own data showed that tens of thousands of women experienced menstrual irregularities after getting the jab as of spring 2022. Kansas attorney general Kris Kobach told the National Review in an interview that the state’s Consumer Protection Act is designed to prevent consumers from being deceived by companies like Pfizer. “They had extraordinary success marketing their vaccine in the state of Kansas and more generally across the globe, and I think that had consumers had this information, many of them might have made a different choice,” he asserted. Sources for this article include: ArmageddonProse.Substack.com NationalReview.com To read the original article, click here: https://www.naturalnews.com/2024-09-20-kansas-sues-pfizer-misleading-public-risks-vaccines.html

The post Kansas Sues Pfizer for Misleading the Public About the Risks of its mRNA COVID-19 Vaccines appeared first on Amazing Health Advances.

UK Gives OK to Merck’s Breakthrough Anti-COVID Pill, Pfizer Announces Its Antiviral Pill Works Too

AHA Publisher — Mon, 08 Nov 2021 08:00:32 +0000

CBN News – The United Kingdom granted conditional authorization Thursday to the first pill officially shown to successfully treat COVID-19. It’s the first country to OK the treatment from drugmaker Merck, but it is not known when the pill will be available to the public. Those with mild to moderate COVID symptoms would take four pills of molnupiravir, twice a day for five days. Adults 18 or older who have tested positive for COVID-19 and who could be at risk for developing severe disease, including people with issues like obesity or heart disease, are slated to be the first patients to receive the pill. Molnupiravir is also pending review with regulators in the U.S., the European Union, and other countries. Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide, so initial supplies of the pill could be limited. “Today is a historic day for our country, as the U.K. is now the first country in the world to approve an antiviral that can be taken at home for COVID-19,” British Health Secretary Sajid Javid said. “We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible,” he said in a statement, referring to the U.K.’s National Health Service. Doctors said the treatment would be particularly significant for people who don’t respond well to vaccination. Merck announced preliminary results in September showing its drug cut hospitalizations and deaths by half among patients with early COVID-19 symptoms. The results haven’t yet been peer-reviewed or published in a scientific journal. Pfizer Announces Another Pill to Fight COVID On Friday, Pfizer also announced it has successfully tested an experimental antiviral pill for COVID-19 as well. Pfizer claims its pill cut rates of hospitalization and death by nearly 90%. Fewer than 1% of patients taking the drug needed to be hospitalized and no one died. “We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer. How Merck’s Drug Works The Merck drug targets an enzyme the coronavirus uses to reproduce itself, inserting errors into its genetic code that slow its ability to spread and take over human cells. That genetic activity has led some independent experts to question whether the drug could potentially cause mutations leading to birth defects or tumors. Britain’s Medicines and Healthcare products Regulatory Agency said molnupiravir’s ability to interact with DNA and cause mutations had been studied “extensively” and that it wasn’t found to pose a risk to humans. “Studies in rats showed that (molnupiravir) may cause harmful effects to the unborn offspring, although this was at doses which were higher than those that will be given to humans, and these effects were not observed in other animals,” the agency said in an email. Last week, Merck agreed to allow other drugmakers to make its COVID-19 pill, in a move aimed at helping millions of people in poorer countries receive the pill. The Medicines Patent Pool, a U.N.-backed group, said Merck will not receive royalties under the agreement for as long as the World Health Organization deems COVID-19 to be a global emergency. The U.S. has agreed to pay roughly $700 per course of the drug for about 1.7 million treatments. Merck says it plans to use a tiered pricing strategy for developing countries. A review by Harvard University and King’s College London estimated the drug costs about $18 to make each 40-pill course of treatment. Will Merck’s Pill Be Approved in the US? As CBN News reported last month, Merck requested U.S. Food and Drug Administration authorization for its COVID pill. The FDA said it would convene a panel of independent experts to scrutinize the pill’s safety and effectiveness later this month. “Of importance is that in the placebo group there were eight deaths, and in the treatment group there were no deaths,” said Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases. “That’s also very important and very good news.” Molnupiravir was initially studied as a potential flu therapy with funding from the U.S. government. Last year, researchers at Emory University decided to repurpose the drug as a potential COVID-19 treatment. They then licensed the drug to Ridgeback and partner Merck. To read the original article click here.

The post UK Gives OK to Merck’s Breakthrough Anti-COVID Pill, Pfizer Announces Its Antiviral Pill Works Too appeared first on Amazing Health Advances.

Pfizer to Seek Approval for COVID Vaccine ‘Within Days’

AHA Publisher — Fri, 20 Nov 2020 08:00:11 +0000

Tré Goins-Phillips, Faithwire via CBN News – The pharmaceutical giant Pfizer announced Wednesday it will seek regulatory approval for its COVID-19 vaccine “within days.” Working in partnership with the German group BioNTech, Pfizer has completed its Phase 3 trial and has deemed the vaccination 95% effective at preventing COVID-19 infections, NBC News reported, up from 90% last week. Former Food and Drug Administration Commissioner Dr. Scott Gottlieb, who serves as an independent member on Pfizer’s board of directors, described the development as a “game change,” adding the successes in vaccine development “could effectively end the U.S. epidemic next year.” To date, there have been no serious side effects for the 41,135 adults who received two doses of the Pfizer vaccine. The most common reaction among trial participants were that 3.7% experienced fatigue and 2% had headaches. Only eight of those who received the Pfizer vaccination fell ill to COVID-19. By comparison, 162 of those who received the placebo became sick. “The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” Pfizer Chairman and CEO Dr. Albert Bourla said in a statement. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.” The companies — Pfizer and BioNTech — announced their joint plan to seek emergency use authorization from the FDA “within days.” The groups are also sharing their findings with regulators in Europe. Pfizer’s data shows the vaccination 95% effective against future infections beginning 28 days after the first two doses. The immunization’s effectiveness was found to be consistent across all age and race demographics. Furthermore, its side effects wore off “shortly after vaccination,” and among older adults, they tended to be “fewer and milder.” News of Pfizer’s rapidly evolving vaccine comes just a couple days after the biotech company Moderna announced its COVID-19 vaccine is 94.5% effective against infection. Moderna President Dr. Stephen Hogue described the development as a “really important milestone,” adding he’s reassured by the fact that Pfizer has released similar findings. “That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” he added. Both the Moderna and Pfizer vaccines were developed using messenger RNA, tiny pieces of genetic code injected into the body to trick the immune system into producing a response to fend off COVID-19 without actually having to inject actual bits of the virus. Anything Else? This week, CNN’s Jake Tapper and Dr. Sanjay Gupta praised President Donald Trump’s administration for its work to facilitate the production of a COVID-19 vaccine at breakneck speed. “It’s important that people working so hard — Monsef Slaoui and the others — get credit for this, and President Trump was the one who OK’d it,” Tapper said. Gupta agreed, adding, “No doubt. The pace of medical innovation has been forever changed. I mean, three months, Jan. 11 is when they got the sequence of this virus. By March 16, two months later, shots were going into arms as part of these clinical trials. I couldn’t believe it when I saw that pace. It typically takes, you know, years to really get these vaccines approved. It’ll be done within a year. That is worth celebrating, and now we have some early data to be very optimistic about.” “So all of the scientists, everyone behind this, all the way up to President Trump and Vice President Pence, congratulations on this great accomplishment,” said Tapper. Trump, for his part, thanked Tapper and Gupta for their comments. To read the original article click here. For more articles from CBN News click here.

The post Pfizer to Seek Approval for COVID Vaccine ‘Within Days’ appeared first on Amazing Health Advances.

Pfizer Says Early Data Signals COVID-19 Vaccine Is Effective

AHA Publisher — Tue, 10 Nov 2020 08:00:02 +0000

Associated Press via CBN News – Pfizer says an early peek at its vaccine data suggests the shots maybe 90% effective at preventing COVID-19, indicating the company is on track later this month to file an emergency use application with U.S. regulators. Monday’s announcement doesn’t mean a vaccine is imminent: This interim analysis, from an independent data monitoring board, looked at 94 infections recorded so far in a study that has enrolled nearly 44,000 people in the U.S. and five other countries. Pfizer Inc. did not provide any more details about those cases and cautioned the initial protection rate might change by the time the study ends. Even revealing such early data is highly unusual. “We’re in a position potentially to be able to offer some hope,” Dr. Bill Gruber, Pfizer’s senior vice president of clinical development, told The Associated Press. “We’re very encouraged.” Authorities have stressed it’s unlikely any vaccine will arrive much before the end of the year, and limited initial supplies will be rationed. The shots made by Pfizer and its German partner BioNTech are among 10 possible vaccine candidates in late-stage testing around the world – four of them so far in huge studies in the U.S. Another U.S. company, Moderna Inc., also has said it hopes to be able to file an application with the Food and Drug Administration later this month. Volunteers in the final-stage studies, and the researchers, don’t know who received the real vaccine or a dummy shot. But a week after their second required dose, Pfizer’s study began counting the number who developed COVID-19 symptoms and were confirmed to have the coronavirus. Because the study hasn’t ended, Gruber couldn’t say how many in each group had infections. Doing the math, that would mean almost all the infections counted so far had to have occurred in people who got the dummy shots. Pfizer doesn’t plan to stop its study until it records 164 infections among all the volunteers, a number that the FDA has agreed is enough to tell how well the vaccine is working. The agency has made clear that any vaccine must be at least 50% effective. No participant so far has become severely ill, Gruber said. Nor could he provide a breakdown of how many of the infections had occurred in older people, who are at the highest risk from COVID-19. Participants were tested only if they developed symptoms, leaving unanswered whether vaccinated people could get infected but show no symptoms and unknowingly spread the virus. FDA has required that U.S. vaccine candidates be studied in at least 30,000 people. In addition to adequate numbers of older adults, those studies must also include other groups at high risk, including minorities and people with chronic health problems. And it told companies they must track half their participants for side effects for at least two months, the time period when problems typically crop up. Pfizer expects to reach that milestone later this month but said Monday no serious safety concerns have been reported. Because the pandemic is still raging, manufacturers hope to seek permission from governments around the world for emergency use of their vaccines while additional testing continues – allowing them to get to market faster than normal but raising concerns about how much scientists will know about the shots. The FDA’s scientific advisers last month said they worry that allowing emergency use of a COVID-19 vaccine could damage confidence in the shots and make it harder to ever find out how well they really work. Those advisers said it’s critical these massive studies are allowed to run to completion. Copyright 2020 The Associated Press. All rights reserved. To read the original article click here. For more articles from CBN News click here.

The post Pfizer Says Early Data Signals COVID-19 Vaccine Is Effective appeared first on Amazing Health Advances.